Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Decline in Short Interest

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 6,220,000 shares, a decline of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is currently 4.9 days.

Analyst Ratings Changes

AUPH has been the subject of a number of recent research reports. StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Aurinia Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise increased its position in Aurinia Pharmaceuticals by 126.6% during the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $84,000. CWM LLC increased its holdings in shares of Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after buying an additional 8,180 shares during the last quarter. FMR LLC increased its holdings in shares of Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after buying an additional 3,919 shares during the last quarter. Finally, PFG Investments LLC raised its position in shares of Aurinia Pharmaceuticals by 37.9% in the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after buying an additional 7,900 shares during the period. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH opened at $9.30 on Monday. The business’s 50-day moving average price is $8.03 and its 200 day moving average price is $6.75. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.67. The company has a market capitalization of $1.33 billion, a PE ratio of -62.46 and a beta of 1.41.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.